Drugs / Human recombinant Interleukin-2
Human recombinant Interleukin-2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02781467 Background | Jul 2016 → Dec 2017 | acute myeloid leukemia | Celularity Incorporated | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human recombinant Interleukin-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02781467 ↗ |
| Known as | Recombinant human interleukin 2 | “The NK cells will be given with chemotherapy and Recombinant human interleukin 2 (rhIL-2) to help the NK cells expand in the body.” NCT02781467 ↗ |
| Known as | rhIL-2 | “Drug: Human recombinant Interleukin-2 (rhIL-2)” NCT02781467 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human interleukin 2 (rhIL-2)” NCT02781467 ↗ |
| Route | Subcutaneous | “Subcutaneous Recombinant Human IL-2 (RHIL-2)” NCT02781467 ↗ |